News
Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...
The Nifty closed the session down 0.82% at 24,565 points, extending its weekly losses for the fifth straight week with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback